Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
Clinical trial NCT03466099 · COMPLETED
Trial details
- NCT number
- NCT03466099
- Sponsor
- KalVista Pharmaceuticals, Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-16
- Primary completion
- 2019-10-10
- Enrollment
- 129
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.